Single User License
INR 239295
Site License
INR 478590
Corporate User License
INR 717885

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Pipeline Review, H2 2016

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Pipeline Review, H2 2016', provides in depth analysis on Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Overview 7

Therapeutics Development 8

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Products under Development by Stage of Development 8

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Products under Development by Therapy Area 9

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Products under Development by Indication 10

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Products under Development by Companies 13

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Products under Development by Universities/Institutes 15

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Companies Involved in Therapeutics Development 24

Ionis Pharmaceuticals, Inc. 24

Neurimmune Holding AG 25

ProMIS Neurosciences Inc. 26

Thera Neuropharma Inc 27

Voyager Therapeutics, Inc. 28

Wilson Therapeutics AB 29

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Drug Profiles 30

ISIS-SOD1Rx-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibodies to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Monoclonal Antibody 1 to Inhibit SOD1 for Amyotrophic Lateral Sclerosis-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Monoclonal Antibody 2 to Inhibit SOD1 for Amyotrophic Lateral Sclerosis-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

NI-204-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TDI-186-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

tetrathiomolybdate-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

THN-1-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

VYSOD-101-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

WTX-101-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Dormant Projects 49

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)-Featured News & Press Releases 50

Jun 23, 2016: Wilson Therapeutics Presents Preliminary Clinical Data on Decuprate at the 20th International Congress of Parkinson's Disease and Movement Disorders 50

May 30, 2016: Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology 50

May 18, 2016: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled 51

Apr 29, 2016: Voyager Therapeutics Highlights Program in ALS Disease 52

Apr 14, 2016: Wilson Therapeutics presents data on Decuprate (WTX101) from ongoing Phase 2 study at The International Liver Congress 2016 52

Dec 11, 2015: Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS 53

Apr 16, 2015: Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015 54

Nov 17, 2014: Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 54

Jan 13, 2014: Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease 55

Apr 03, 2013: MGH And Washington University Researchers Announce Isis Pharma's SOD1 Antisense Drug Demonstrates Safety In Phase I ALS Trial 55

Feb 13, 2013: Copper Depletion Therapy May Prevent Risk Of Triple-Negative Breast Cancer, Study Finds 57

Apr 28, 2011: RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant for RNAi Therapeutics for ALS 59

Mar 08, 2010: ISIS Initiates Phase I Clinical Trial Of ISIS-SOD1Rx In Patients With Amyotrophic Lateral Sclerosis 60

Dec 13, 2007: Isis Pharmaceuticals Announces ISIS 333611 Granted Orphan Drug Status For Treatment Of ALS 60

May 24, 2004: Attenuon Announces Launch Of ATN-224 Phase I Trial In Patients With Solid Tumors 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 24

Pipeline by Neurimmune Holding AG, H2 2016 25

Pipeline by ProMIS Neurosciences Inc., H2 2016 26

Pipeline by Thera Neuropharma Inc, H2 2016 27

Pipeline by Voyager Therapeutics, Inc., H2 2016 28

Pipeline by Wilson Therapeutics AB, H2 2016 29

Dormant Projects, H2 2016 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ionis Pharmaceuticals, Inc., Neurimmune Holding AG, ProMIS Neurosciences Inc., Thera Neuropharma Inc, Voyager Therapeutics, Inc., Wilson Therapeutics AB

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Therapeutic Products under Development, Key Players in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Therapeutics, Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Pipeline Overview, Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Pipeline, Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com